

REMARKS

The Non-Final Office Action mailed March 24, 2005 has been carefully considered. Claims 1-72 are currently pending. No new matter has been added by this Amendment.

Objections to the Specification

The abstract of the disclosure was objected to because legal phraseology was used. The abstract is currently amended to delete the term "comprises." Therefore, this objection is believed to be obviated.

Double Patenting Rejection

Claims 1-72 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-37 of U.S. Patent No. 6,656,162 ("the '162 patent").

To overcome this rejection, Applicants file concurrently herewith a Terminal Disclaimer in compliance with 37 C.F.R. § 1.321(c). The '162 patent is related to the instant application, as the instant application is a continuation of the '162 patent. Furthermore, the '162 patent and the instant application are commonly owned by Boston Scientific Scimed, Inc. Therefore, Applicants submit that this rejection should be withdrawn.


CONCLUSION

It is believed that pending claims 1-72 are in condition for allowance.

A 3-month extension fee in the amount of \$1020 is believed due for this response. Please charge this fee, and any other fee(s) that may be due, to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: September 20, 2005


Brent P. Ray
For: Gidon D. Stern
(Reg. No. 27,469)

54,390
(Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939